By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks - 26 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- 3Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- 4Most loved Occasion Dish: What Makes Your Merry Table?
- 5Experience Is standing by: History's Most noteworthy Travelers
- Pick Your Favored kind of sandwich
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
- Germany paves the way for tighter EU asylum rules
- Russia confirms 16 Cameroonian soldiers killed in Ukraine war
- Fundamental Archives for Beginning Your Business
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- Farmers call for French blockades over cow disease cull
